BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 35695190)

  • 1. Distribution and favorable prognostic implication of genomic EGFR alterations in IDH-wildtype glioblastoma.
    Higa N; Akahane T; Hamada T; Yonezawa H; Uchida H; Makino R; Watanabe S; Takajo T; Yokoyama S; Kirishima M; Matsuo K; Fujio S; Hanaya R; Tanimoto A; Yoshimoto K
    Cancer Med; 2023 Jan; 12(1):49-60. PubMed ID: 35695190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A longer time to relapse is associated with a larger increase in differences between paired primary and recurrent IDH wild-type glioblastomas at both the transcriptomic and genomic levels.
    Ho WM; Chen CY; Chiang TW; Chuang TJ
    Acta Neuropathol Commun; 2024 May; 12(1):77. PubMed ID: 38762464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-expression of cancer driver genes: IDH-wildtype glioblastoma-derived tumorspheres.
    Yoon SJ; Son HY; Shim JK; Moon JH; Kim EH; Chang JH; Teo WY; Kim SH; Park SW; Huh YM; Kang SG
    J Transl Med; 2020 Dec; 18(1):482. PubMed ID: 33317554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging predictors of 4q12 amplified and RB1 mutated glioblastoma IDH-wildtype.
    Dono A; Torres J; Nunez L; Arevalo O; Rodriguez-Quinteros JC; Riascos RF; Kamali A; Tandon N; Ballester LY; Esquenazi Y
    J Neurooncol; 2024 Mar; 167(1):99-109. PubMed ID: 38351343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization.
    Wilcock DM; Goold E; Zuromski LM; Davidson C; Mao Q; Sirohi D
    J Neuropathol Exp Neurol; 2024 Apr; 83(5):338-344. PubMed ID: 38605523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic landscape of glioblastoma without IDH somatic mutation in 42 cases: a comprehensive analysis using RNA sequencing data.
    Okamoto T; Mizuta R; Takahashi Y; Otani Y; Sasaki E; Horio Y; Kuroda H; Matsushita H; Date I; Hashimoto N; Masago K
    J Neurooncol; 2024 May; 167(3):489-499. PubMed ID: 38653957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining genomic analyses with tumour-derived slice cultures for the characterization of an EGFR-activating kinase mutation in a case of glioblastoma.
    Loriguet L; Morisse MC; Dremaux J; Collet L; Attencourt C; Coutte A; Boone M; Sevestre H; Galmiche A; Gubler B; Chauffert B; Trudel S
    BMC Cancer; 2018 Oct; 18(1):964. PubMed ID: 30305059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrated genomic analysis of human glioblastoma multiforme.
    Parsons DW; Jones S; Zhang X; Lin JC; Leary RJ; Angenendt P; Mankoo P; Carter H; Siu IM; Gallia GL; Olivi A; McLendon R; Rasheed BA; Keir S; Nikolskaya T; Nikolsky Y; Busam DA; Tekleab H; Diaz LA; Hartigan J; Smith DR; Strausberg RL; Marie SK; Shinjo SM; Yan H; Riggins GJ; Bigner DD; Karchin R; Papadopoulos N; Parmigiani G; Vogelstein B; Velculescu VE; Kinzler KW
    Science; 2008 Sep; 321(5897):1807-12. PubMed ID: 18772396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic profiling reveals a strong association between lack of 5-ALA fluorescence and
    Drexler R; Sauvigny T; Schüller U; Eckhardt A; Maire CL; Khatri R; Hausmann F; Hänzelmann S; Huber TB; Bonn S; Bode H; Lamszus K; Westphal M; Dührsen L; Ricklefs FL
    Neurooncol Pract; 2023 Oct; 10(5):462-471. PubMed ID: 37720395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma.
    Lim-Fat MJ; Iorgulescu JB; Rahman R; Bhave V; Muzikansky A; Woodward E; Whorral S; Allen M; Touat M; Li X; Xy G; Patel J; Gerstner ER; Kalpathy-Cramer J; Youssef G; Chukwueke U; McFaline-Figueroa JR; Nayak L; Lee EQ; Reardon DA; Beroukhim R; Huang RY; Bi WL; Ligon KL; Wen PY
    Clin Cancer Res; 2024 Apr; 30(7):1327-1337. PubMed ID: 38252427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of
    Dono A; Ramesh AV; Wang E; Shah M; Tandon N; Ballester LY; Esquenazi Y
    Neurooncol Adv; 2021; 3(1):vdab050. PubMed ID: 34131647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extent of Resection Thresholds in Molecular Subgroups of Newly Diagnosed Isocitrate Dehydrogenase-Wildtype Glioblastoma.
    Dono A; Zhu P; Takayasu T; Arevalo O; Riascos R; Tandon N; Ballester LY; Esquenazi Y
    Neurosurgery; 2024 Apr; ():. PubMed ID: 38687046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models.
    Álvarez-Vázquez A; San-Segundo L; Cerveró-García P; Flores-Hernández R; Ollauri-Ibáñez C; Segura-Collar B; Hubert CG; Morrison G; Pollard SM; Lathia JD; Sánchez-Gómez P; Tabernero A
    Neuro Oncol; 2024 Mar; ():. PubMed ID: 38507464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glioblastoma, IDH-Wildtype With Epithelioid Morphology and a
    Umeres-Francia GE; Arias-Stella JA; Manoukian S; Arvanitis L
    Int J Surg Pathol; 2024 Apr; ():10668969241239679. PubMed ID: 38562049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leptomeningeal Dissemination Complicated With Acute Tetraplegia From a Supratentorial Multicentric Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastoma: A Case Report.
    Visarion DM; Cale I; Miron I; David BI; Petrescu GE; Pruna VM
    Cureus; 2024 Mar; 16(3):e55777. PubMed ID: 38586710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of
    Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Otsuji R; Hamada T; Matsuo K; Kirishima M; Hata N; Hanaya R; Tanimoto A; Yoshimoto K
    Neurooncol Adv; 2022; 4(1):vdac097. PubMed ID: 35911637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Genetic Profile of 300 Japanese Patients with Diffuse Gliomas Using a Glioma-tailored Gene Panel.
    Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Fujio S; Kirishima M; Takigawa K; Hata N; Toh K; Yamamoto J; Hanaya R; Tanimoto A; Yoshimoto K
    Neurol Med Chir (Tokyo); 2022 Sep; 62(9):391-399. PubMed ID: 36031351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable prognostic impact of
    Higa N; Akahane T; Yokoyama S; Makino R; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Noguchi N; Otsuji R; Kuga D; Nagasaka S; Yamahata H; Yamamoto J; Yoshimoto K; Tanimoto A; Hanaya R
    Neurooncol Adv; 2023; 5(1):vdad078. PubMed ID: 37528810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular landscapes of glioblastoma cell lines revealed a group of patients that do not benefit from
    Kałuzińska-Kołat Ż; Kołat D; Kośla K; Płuciennik E; Bednarek AK
    Front Neurosci; 2023; 17():1260409. PubMed ID: 37781246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in
    Makino R; Higa N; Akahane T; Yonezawa H; Uchida H; Takajo T; Fujio S; Kirishima M; Hamada T; Yamahata H; Kamimura K; Yoshiura T; Yoshimoto K; Tanimoto A; Hanaya R
    Neurooncol Adv; 2023; 5(1):vdad110. PubMed ID: 37744696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.